Last checked at 2 Oct 2023 17:53
Â
Allergy Therapeutics plc
("Allergy Therapeutics", the "Group" or "Company")
Â
Extension of Block Admission
Â
Block Listing Interim Review
Â
2 October 2023 Allergy Therapeutics plc (AIM: AGY) announces that an application has been made to the London Stock Exchange for a block admission of 5,000,000 ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") to be admitted to trading on AIM.
The Ordinary Shares may be issued pursuant to the exercise of share options under Allergy Therapeutics plc 2013 Long Term Incentive Plan and will, upon issue, rank pari passu in all respects with the Company's existing Ordinary Shares. Following this increase, the total Block Listing will consist of 12,013,147 Ordinary Shares.
It is expected that admission will become effective on 5 October 2023. When issued, the Ordinary Shares will rank pari passu with the existing ordinary shares of the Company.
Â
Block Listing Interim Review
Â
Name of applicant: | ALLERGY THERAPEUTICS PLC | |||
Name of scheme: | Allergy Therapeutics plc 2013 Long Term Incentive Plan | |||
Period of return: | From: | 1 March 2023 | To: | 30 September 2023 |
Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission: | 10,000,000 ordinary shares of 0.1p each in the Company admitted to trading on 24 November 2017 Additional listing of 7,000,000 ordinary shares of 0.1p each in the Company admitted to trading on 7 April 2021 | |||
Balance of unallotted securities under scheme(s) from previous return: | 7,013,772 ordinary shares* | |||
Plus:Â The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
Less:Â Number of securities issued/allotted under scheme(s) during period: | Nil | |||
Equals:Â Balance under scheme(s) not yet issued/allotted at end of period: | 7,013,772 ordinary shares | |||
Â
Name of contact: | Karley Cheesman |
Telephone number of contact: | +44 (0) 1903 844 700 |
*The balance of unallotted securities under the scheme from the previous return has been updated to account for 105,625 ordinary shares that were issued during the previous review period.
Â
For further information, please contact:
Â
Allergy Therapeutics
Manuel Llobet, Chief Executive Officer
Shaun Furlong, Chief Financial Officer
+44 (0)1903 845 820
Â
Panmure Gordon (Nominated Adviser and Broker)
Emma Earl, Mark Rogers, Freddy Crossley, Corporate Finance
Rupert Dearden, Corporate Broking
+44 (0)20 7886 2500
Â
Consilium Strategic Communications
Mary-Jane Elliott / David Daley / Davide Salvi
+44 (0)20 3709 5700
allergytherapeutics@consilium-comms.com
Â
Â
Notes for editors:
Â
About Allergy Therapeutics
Â
Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see www.allergytherapeutics.com.